Here, we describe a patient with newly diagnosed metastatic NSCLC with a common EGFR mutation, a PIK3CA mutation and CDK4 amplification, who benefited from combined osimertinib and palbociclib treatment after disease progression on treatment with osimertinib alone. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.